International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

Leukemia

Volumn 23, Issue 2, 2009, Pages 215-224

  Dispenzieri, Angela ^a   Kyle, R ^a   Merlini, G ^b   Miguel, J S ^c   Ludwig, H ^d   Hajek, R ^e   Palumbo, A ^f   Jagannath, S ^g   Blade, J ^h   Lonial, S ⁱ   Dimopoulos, M ^j   Comenzo, R ^k   Einsele, H ^l   Barlogie, B ^m   Anderson, K ⁿ   Gertz, M ^a   Harousseau, J L ^o   Attal, M ^p   Tosi, P ^q   Sonneveld, P ^r   Boccadoro, M ^f   Morgan, G ^s   Richardson, P ⁿ   Sezer, O ^t   Mateos, M V ^c   Cavo, M ^q   Joshua, D ^u   Turesson, I ^v   Chen, W ^w   Shimizu, K ^x   Powles, R ^y   Rajkumar, S V ^a   Durie, B G M ^z   more..

^a MAYO CLINIC   (United States)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^d WILHELMINEN HOSPITAL   (Austria)

^e UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^f UNIVERSITY OF TURIN   (Italy)

^g ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ EMORY UNIVERSITY   (United States)

^j ALEXANDRA HOSPITAL   (Greece)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l UNIVERSITY OF WÜRZBURG   (Germany)

^m UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

ⁿ DFCI   (United States)

^o INSTITUT DE BIOLOGIE   (France)

^p CHU PURPAN   (France)

^q UNIVERSITY OF BOLOGNA   (Italy)

^r ERASMUS MEDICAL CENTER   (Netherlands)

^s The Leukemia and Myeloma Program   (United Kingdom)

^t HUMBOLDT UNIVERSITY   (Germany)

^u ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^v LUND UNIVERSITY HOSPITAL   (Sweden)

^w CAPITAL MEDICAL UNIVERSITY   (China)

^x Nagoya City Higashi General Hospital   (Japan)

^y Parkside Cancer Centre   (United Kingdom)

^z CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; M PROTEIN; THALIDOMIDE;

AMYLOIDOSIS; CAPILLARY ZONE ELECTROPHORESIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; HUMAN; IMMUNOASSAY; IMMUNOGLOBULIN BLOOD LEVEL; LIGHT CHAIN; LIGHT CHAIN AMYLOIDOSIS; LYMPHOPROLIFERATIVE DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PATIENT MONITORING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PLASMACYTOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ELECTROPHORESIS; PROTEIN URINE LEVEL; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SERUM FREE LIGHT CHAIN ASSAY; TREATMENT RESPONSE;

EID: 60149096306     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.307     Document Type: Review

References (43)

1. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47: 673-680.
2. Bradwell AR. Serum free light chain measurements move to center stage. Clin Chem 2005; 51: 805-807.
3. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361: 489-491.
4. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 48: 1437-1444.
5. Nakano T, Nagata A. ELISAs for free light chains of human immunoglobulins using monoclonal antibodies: Comparison of their specificity with available polyclonal antibodies. J Immunol Methods 2003; 275: 9-17.
6. Tate JR, Mollee P, Dimeski G, Carter AC, Gill D. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clin Chim Acta 2007; 376: 30-36.
7. Daval S, Tridon A, Mazeron N, Ristori JM, Evrard B. Risk of antigen excess in serum free light chain measurements. Clin Chem 2007; 53: 1985-1986.
8. Le Bricon T, Bengoufa D, Benlakehal M, Bousquet B, Erlich D. Urinary free light chain analysis by the Freelite immunoassay: A preliminary study in multiple myeloma. Clin Biochem 2002; 35: 565-567.
9. Snozek CL, Katzmann JA, Kyle RA, Dispenzieri A, Larson DR, Therneau TM et al. Prognostic value of the serum-free light chain ratio in patients with newly diagnosed myeloma and proposed incorporation into the International Staging System. Leukemia 2008; 22: 1933-1937.
10. Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR. Serum-free light chains for monitoring multiple myeloma. Br J Haematol 2004; 126: 348-354.
11. Kang SY, Suh JT, Lee HJ, Yoon HJ, Lee WI. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma. Ann Hematol 2005; 84: 588-593.
12. Dispenzieri A, Zhang L, Katzmann JA, Snyder M, Blood E, Degoey R et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood 2008; 111: 4908-4915.
13. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97: 2900-2902.
14. Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA. Diagnostic performance of quantitative {kappa} and {lambda} free light chain assays in clinical practice. Clin Chem 2005; 51: 878-881.
15. Abraham RS, Clark RJ, Bryant SC, Lymp JF, Larson T, Kyle RA et al. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chem 2002; 48: 655-657.
16. Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008; 111: 785-789.
17. Rajkumar SV, Kyle RA, Therneau TM, Melton III LJ, Bradwell AR, Clark RJ et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106: 812-817.
18. Abraham RS, Katzmann JA, Clark RJ, Bradwell AR, Kyle RA, Gertz MA. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003; 119: 274-278.
19. Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003; 122: 78-84.
20. Katzmann JA, Dispenzieri A, Kyle RA, Snyder MR, Plevak MF, Larson DR et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc 2006; 81: 1575-1578.
21. Beetham R, Wassell J, Wallage MJ, Whiteway AJ, James JA. Can serum free light chains replace urine electrophoresis in the detection of monoclonal gammopathies? Ann Clin Biochem 2007; 44: 516-522.
22. Nowrousian MR, Brandhorst D, Sammet C, Kellert M, Daniels R, Schuett P et al. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res 2005; 11: 8706-8714.
23. Hill PG, Forsyth JM, Rai B, Mayne S. Serum free light chains: An alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies. Clin Chem 2006; 52: 1743-1748.
24. Abadie JM, Bankson DD. Assessment of serum free light chain assays for plasma cell disorder screening in a veterans affairs population. Ann Clin Lab Sci 2006; 36: 157-162.
25. Bakshi NA, Gulbranson R, Garstka D, Bradwell AR, Keren DF. Serum free light chain (FLC) measurement can aid capillary zone electrophoresis in detecting subtle FLC-producing M proteins. Am J Clin Pathol 2005; 124: 214-218.
26. Marien G, Oris E, Bradwell AR, Blanckaert N, Bossuyt X. Detection of monoclonal proteins in sera by capillary zone electrophoresis and free light chain measurements. Clin Chem 2002; 48: 1600-1601.
27. Kumar S, Fonseca R, Dispenzieri A, Katzmann JA, Kyle RA, Clark R et al. High incidence of IgH translocations in monoclonal gammopathies with abnormal free light chain levels. ASH Annual Meeting Abstracts 2006; 108: 3514.
28. Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006; 107: 3378-3383.
29. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007; 110: 827-832.
30. Kyle RA, Remstein E, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield J et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. New Engl J Med 2007; 356: 2582-2590.
31. Dingli D, Kyle RA, Rajkumar SV, Nowakowski GS, Larson DR, Bida JP et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood 2006; 108: 1979-1983.
32. Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, Sachanas S, Tzenou T, Papadogiannis A et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol 2007; 137 240-243.
33. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
34. Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006; 107: 3854-3858.
35. Sanchorawala V, Seldin DC, Magnani B, Skinner M, Wright DG. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant 2005; 36: 597-600.
36. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79: 319-328.
37. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
38. Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone+/-thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol 2007; 139: 224-233.
39. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
40. Singhal S, Stein R, Vickrey E, Mehta J. The serum-free light chain assay cannot replace 24-h urine protein estimation in patients with plasma cell dyscrasias. Blood 2007; 109: 3611-3612.
41. Hajek R, Cermakova Z, Pour L, Novontna H, Maisnar V, Tichy M et al. Free light chain assays for early detection of resistance to bortezomib-based regimens. Haematologica 2007; 92: 93.
42. Hassoun H, Reich L, Klimek VM, Dhodapkar M, Cohen A, Kewalramani T et al. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br J Haematol 2006; 132: 155-161.
43. Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica 2007; 92: 143-144.